UNSPSC 51162701: Acetylcysteine

This classification denotes a mucolytic agent and antioxidant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) WYQ7N0BPYC. European Medicines Agency schedules Acetylcysteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05229MIG. Acetylcysteine generally arises in the molecular formula C5H9NO3S. The term ACETYLCYSTEINE is an International Nomenclature of Cosmetic Ingredients designation.

UNSPSC 51162701 Acetylcysteine is a Commodity code nominally for a single pharmaceutical ingredient, yet the recent state and local opportunities posted under it reflect a broader procurement pattern: acquisition of generic pharmaceuticals, naloxone, drug deactivation systems, and over-the-counter products for public health delivery. State and local buyers under this code include county health departments, state multistate cooperative purchasing alliances, and special-purpose health districts. The scope spans product procurement ranging from emergency-response medications (naloxone) to generic pharmaceutical supplies distributed through authorized wholesalers and delivered to community health facilities. Issuers posting under this code include individual counties managing community health initiatives and multistate cooperative purchasing vehicles administering statewide pharmaceutical frameworks.

Geographic activity centers on Florida and Minnesota, with the MMCAP cooperative purchasing vehicle extending reach across participating states including Oregon. Recent representative opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities, with pricing evaluated on fixed rates (10 percent weight), compliance with data format requirements (5 percent), EDI capability (5 percent), administrative fee agreement (5 percent), and price competitiveness (75 percent). MMCAP requires vendors to supply through three authorized wholesalers with cGMP and DSCSA compliance, maintain $5,000,000 commercial general liability coverage, and accept a 3 percent administrative fee on purchases.